The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Deutz AG
Advised Marine Service business Deutz on the sale of its marine service business for medium and large size engines to Wärtsilä
Republic Companies Group, Inc.
Advised Republic Companies Group, Inc., a regional provider of personal and commercial property and casualty insurance products
Tele2 AB’s fixed telephony and broadband business in France
Advised SFR S.A., the second largest mobile telecoms operator in France on the acquisition of the French fixed telephony and broadband business of Tele2 AB
IPSCO Inc.
Acted as lead financial advisor to SSAB Svenskt Stål AB on its acquisition of IPSCO Inc., a leading Canadian producer of energy tubulars and steel plate in North America with an annual steel making capacity of 4.3 million tons
Schenck Process Holding GmbH
Advised HgCapital on the sale of Schenck Process, one of the global market leading providers of industrial weighing, feeding, screening and automation equipment and solutions
Scholastic Corporation’s US direct-to-home continuities business
Advised Scholastic, the global children’s publishing, education and media company, on the sale of its US direct-to-home continuities business to Sandvik AS
SAS Group
Advised the Norwegian Government on strategic and financial matters in relation to a refinancing including a conditional capital injection in SAS, the leading airline group in Northern Europe
Taro Pharmaceutical Industries
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
Aker Solutions (Aker Holding)
Advised the Norwegian Government on strategic and financial matters in relation to its investment in Aker Holding, the largest shareholder of Aker Solutions during the demerger of the company’s EPC activities
KemFine Group Oy
Advised 3i on the disposal of KemFine Group Oy, a leading custom manufacturer of fine chemicals, to CABB AG
KEMA
Advised Det Norske Veritas, a global provider of services for managing risk, on its acquisition of a 74.3% stake in KEMA, a leading provider of energy consulting and testing & certification services
Germanischer Lloyd
Advised Det Norske Veritas on its merger with Germanischer Lloyd to create the third largest player in the Testing, Inspection and Certification industry, focused on ship classification, oil & gas and energy
Unfors Raysafe AB
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
Atwood Mobile Products, LLC
Advised Dometic Group AB, a portfolio company of EQT, on its acquisition of Atwood Mobile Products, a global manufacturer of appliances and hardware for the RV, On-/Off-Highway and Marine industries
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
36.5% stake in DNV GL Group AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL